The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Roche (Inst)
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; Genzyme; IPSEN; Janssen-Cilag; Lexicon; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - AstraZeneca (Inst); Ipsen (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche/Genentech
 
Félix Guerrero
No Relationships to Disclose
 
Javier Puente
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche
 
Isabel Galante
No Relationships to Disclose
 
Ignacio Duran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Ipsen; Roche/Genentech
 
Mario Dominguez
No Relationships to Disclose
 
Teresa Alonso Gordoa
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Research Funding - Ipsen; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer; Sanofi
 
Javier Burgos
No Relationships to Disclose
 
Albert Font
No Relationships to Disclose
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Mario Alvarez-Maestro
No Relationships to Disclose
 
Oscar Reig
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
José Maroto
No Relationships to Disclose
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Pfizer; PharmaMar
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Patricia Galvan
No Relationships to Disclose
 
Juan Fernando Garcia
No Relationships to Disclose
 
Nuria Malats
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Amgen; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Francisco X. Real
No Relationships to Disclose
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche